Vivus Fails to Win FDA Panel’s Recommendation for Weight-Loss Pill Qnexa
Vivus Inc. , an unprofitable biotechnology company, failed to win a U.S. panel’s backing to sell the first new prescription diet pill in more than a decade. Shares of competitors dropped, while Vivus trading was halted.
Read more on Bloomberg
Sector Snap: Obesity drugmakers rise on study
Shares of obesity drug developers rose Thursday following a report that Arena Pharmaceuticals Inc.’s lorcaserin prompted weight loss without heart-related side effects. On Wednesday, a study showed that lorcaserin caused more people to lose at least 5 percent… Arena Pharmaceutical – Weight loss – Obesity – Health – Anti-obesity medication
Read more on San Francisco Chronicle
Related posts:
- Vivus’s Qnexa Will Become Decision Resources’ Clinical Gold Standard In 2013 For The Treatment Of Obesity
- Vivus, Arena Obesity Drugs Won’t Be Judged by Fen-Phen Risk, U.S. FDA Says
- Treatment Effects of Xenical Weight Loss Pill
- What Is The Best Multi-Vitamin Recommendation For The Alli Pill?
- Herbal Diet Pill To Speed Up Weight Loss – Does It Work?
Tags: Fails, Panel's, Pill, Qnexa, Recommendation, Vivus, WeightLoss